Subsequently, phase 2 and 3 clinical trials, which included patients with BRCA1/2-mutated breast, ovarian, pancreatic, and prostate cancers, demonstrated the clinical benefit offered by olaparib [88–92], thus providing sufficient evidence for the FDA to approve olaparib as a treatment for advanced ovarian cancer patients [93, 94]. This evidence concerns the gene BRCA1 and prostate cancer.